1. Spain Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Grifols, S.A.

Grifols, S.A.

GIFLF
Grifols, S.A.US flagOther OTC
11.12
USD
- -
- -
7.57BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.03
4.9
5.74
5.93
6.31
6.55
7.44
7.79
7.24
8.92
9.7
10.61
11.06
10.91
Basic EPS, GAAP
0.51
0.69
0.78
0.8
0.97
0.87
0.91
0.9
0.28
0.27
0.06
0.23
0.59
0.44
Free Cash Flow per Basic Share
0.62
1.01
0.26
0.38
0.76
0.63
0.23
1.09
0.41
-0.58
-0.14
0.78
0.92
1.4
Dividend per Share
0.1
0.23
0.32
0.32
0.32
0.41
0.35
0.17
0.38
- -
- -
- -
0.19
- -
Book Value per Share
0.58
0.74
0.78
0.79
0.96
0.85
0.89
1.08
0.45
0.18
0.24
0.41
0.62
0.43
Tangible Book Value per Share
-0.98
-2.31
-2.03
-1.63
-3.25
-2.77
-0.14
-0.25
-0.81
-2.92
-3.12
-2.54
-2.88
-2.93
Basic Weighted Avg Shares
681
685
685
683
684
685
685
686
682
680
680
680
681
682
Sales/Revenue/Turnover
2,742
3,355
3,935
4,050
4,318
4,487
5,099
5,340
4,933
6,064
6,592
7,212
7,524
7,446
Operating Margin (%)
26.85
25.56
24.66
23.2
23.24
22.16
22.01
18.26
11.4
11.2
10.89
16.01
16.63
17.8
Depreciation Expense
128
189
190
202
215
229
302
322
360
411
446
438
450
437
Net Income, GAAP
346
470
532
545
663
597
625
619
189
185
42
157
402
298
Effective Tax Rate (%)
31.25
20.79
23.01
23.6
4.95
18.11
20.62
19.31
24.29
26.66
20.87
52.03
18.7
37.66
Profit Margin (%)
12.6
14.01
13.52
13.47
15.35
13.3
12.26
11.58
3.83
3.05
0.64
2.18
5.34
4
Working Capital
1,424
1,833
2,036
2,051
1,967
2,226
3,996
1,830
2,036
2,671
3,806
3,572
3,055
3,256
LT Debt
2,438
4,072
4,572
4,681
5,878
6,021
6,786
6,592
6,930
9,069
9,985
9,445
9,043
8,425
Total Equity
2,107
2,663
3,301
3,728
3,634
4,697
6,846
6,720
7,317
7,976
7,514
8,606
7,603
7,598
Return on Invested Capital (%)
10.7
11.52
9.9
8.58
10.42
7.99
7.22
5.7
2.81
2.9
3.14
2.97
5.65
5.48
Return on Capital (%)
15.91
16.19
14.06
13.44
14.89
11.97
10.22
7.45
2.8
3.79
2.58
2.95
6.07
4.03
Return on Common Equity (%)
89.64
104.46
102.73
101.55
110.31
96.32
105.29
91.9
36.07
86.48
29.84
71.54
115.35
57.56

Capital Structure

FRC

•

in mil. unless spec.
Jun'21
Mar'25
Jun'25
ST Debt
900
- -
394
LT Borrowings
5,968
- -
7,448
LT Finance Leases
738
- -
978
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
679
- -
680
Market Capitalization
15,089
7,268
6,628

Working Capital

FRC

•

in mil. unless spec.
Jun'21
Mar'25
Jun'25
Total Current Assets
3,240
- -
5,246
Cash, Cash Equivalents & STI
408
- -
566
Accounts Receivable, Net
532
- -
749
Inventories
2,124
- -
3,347
Total Current Liabilities
1,921
- -
1,990
Payables & Accruals
787
- -
1,181
ST Debt
900
- -
394
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.85%
3%
-11.65%
Free Cash Flow
-58.67%
-206.15%
17.74%
Net Income, GAAP
29.89%
56.22%
156.05%
Sales/Revenue/Turnover
6.96%
7.55%
4.33%
Total Cash Common Dividend
- -
- -
12,700%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,818
1,793
1,976
- -
7,212
2025
1,786
1,891
1,982
- -
7,524
2026
1,700
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.08
0.1
- -
0.23
2025
0.09
0.17
- -
- -
0.59
2026
0.11
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.19
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Jose Ignacio Abia Buenache
Full Time Employees
23,833
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
Avinguda de la Generalitat, 152 Barcelona Spain 08174
IPO Date
Jun 24, 2008
CIK
0001438569
Website
grifols.com
Similar Companies
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ)
PharmGen Science, Inc. (004720.KS)
Impact Therap-b (7630.HK)
Sanofi (SNW.DE)
Chugai Pharmaceutical Co., Ltd. (CHGCY)
Virbac S.A. (VRBCF)
Business
Grifols, S.A. (NASDAQ: GRFS; BME: GRLS) is a leading global healthcare company that develops, manufactures and markets plasma-derived medicines, biopharmaceuticals and solutions in transfusion medicine, diagnostics, and life sciences; its core products include plasma protein therapies for immunology (such as immune globulins like Xembify and Yimmugo), pulmonology (albumin and alpha-1 antitrypsin), infectious diseases, neurology, hematology, hepatology and critical care, alongside diagnostic reagents, instruments and equipment for blood screening and clinical testing, and biological materials like plasma and proteins for research, clinical trials and pharmaceutical manufacturing. Founded in 1909 and headquartered in Sant Cugat del Vallès near Barcelona, Spain, the company operates in over 110 countries with a direct presence in more than 30 countries and regions, including the world's largest network of approximately 400 plasma donation centers primarily in North America, Europe and through partnerships in China and Africa. Grifols serves patients with rare, chronic and life-threatening conditions, hospitals, pharmacies, blood banks and life science researchers, focusing on therapeutic areas where plasma-based treatments often represent the only viable options. In recent developments, Grifols reports strong financial performance with 7% revenue growth to EUR 3,677 million and net profit of EUR 177 million in the first half of 2025, alongside plans to double plasma fractionation capacity in Europe via a new manufacturing facility in Spain operational by mid-2025 as part of its Value Creation Plan; the company completed the delisting of Biotest in June 2025 following its 2022 acquisition, appointed Anne-Catherine Berner as Chair and Tomás Dagá to key roles, created a Board Strategy Committee, secured investor support for refinancing EUR 1.3 billion in notes, and received positive credit rating revisions from Fitch and Moody's.[web:press:2025]

Company News

APIChat

  • seekingalpha.com

    Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript